TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Cellino has launched Reservoir, a consumer service that collects and cryopreserves adults’ immune cells, with pricing typically starting around $5,000 and annual storage costing $270 after the first year. The company says the cells could offer future medical options, but their usefulness for healthy customers has not been established.
Biotech company Cellino has launched Reservoir, a service for adults to preserve immune cells collected through a blood draw, at a typical starting price of about $5,000. The company is pitching the service as a way to keep cells for possible future medical use, but whether banking cells in advance will benefit healthy customers remains uncertain.
Reservoir’s process begins with a blood draw at a partner clinic or, in select areas, an at-home appointment. Cellino says it isolates peripheral blood mononuclear cells, or PBMCs, which include T cells, B cells, natural killer cells and monocytes. The cells are counted, cryopreserved and stored at temperatures below -150°C at an FDA-registered facility, according to the company.
The usual starting price is about $5,000, covering collection, processing, preservation and the first year of storage. Cellino lists an ongoing fee of $270 per year after that, with prices varying by clinic. The company says members retain ownership of their samples and that cells can be released only at the member’s request, in coordination with a licensed physician.
The service is open to adults 18 and older. At launch, partner clinics were available in markets including San Francisco, Los Angeles, New York and Boston; at-home collection was offered in select locations. Cellino said it planned to add markets and offered a nationwide waitlist through Reservoir’s website.
A New Consumer Option, Not a Proven Therapy
Reservoir brings a laboratory preservation service into the consumer longevity market, asking customers to pay now for biological material they might want to use if relevant treatments become available later. The potential appeal is straightforward: cells collected at a younger age may differ from those collected years later. Cellino’s case is that keeping a sample could preserve future choices.
That possibility should not be confused with an established health benefit. The source report does not identify a proven treatment that customers can access by banking these cells, or clinical evidence that the service improves longevity or health outcomes. For prospective customers, the near-term decision is therefore about cost, storage and uncertain future utility, rather than a demonstrated intervention.
The model also shifts part of the discussion around personalized medicine toward consumers. Cellino is not only developing technology for manufacturing cell therapies; through Reservoir, it is selling individuals a way to store their own cells. Whether those samples become useful will depend on future science, medical practice and the ability to use stored cells safely and effectively.
As an affiliate, we earn on qualifying purchases.
Cellino’s Move Beyond Therapy Manufacturing
Cellino, based in Cambridge, Massachusetts, was co-founded in 2017 by Nabiha Saklayen and Marinna Madrid. Its core business is developing AI-powered, autonomous manufacturing technology intended to support personalized cell therapies. The company has raised more than $96 million from investors named in the report, including Khosla Ventures, 8VC, Felicis and Leaps by Bayer.
The report also says Cellino received an award of up to $25 million from ARPA-H and an FDA Advanced Manufacturing Technology designation for its manufacturing platform. Those company and platform credentials provide context for the launch, but they do not establish that Reservoir’s service has a proven longevity effect or that its stored cells will be suitable for a particular future treatment.
Cellino CEO Saklayen told Athletech News that people who heard about the company’s work repeatedly asked whether they could preserve their own cells. The company says Reservoir was designed to make such storage accessible to consumers, rather than limiting it to research or specialized medical settings.
“Cell preservation is unique because it is fundamentally about optionality: preserving your cells as they are today, so that whatever the science makes possible later, you still have the material to use.”
— Jay Luthar, Harvard Medical School faculty member and founder of partner clinic Lutanen Health
cryopreservation storage container
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Future Uses and Customer Benefits
The central uncertainty is whether a customer’s stored immune cells will have a useful, safe and practical medical application. The report describes possible future use but does not cite an established treatment specifically enabled by Reservoir samples, nor evidence that banking them improves health outcomes for otherwise healthy adults.
Details that could shape a customer’s decision are also not fully specified in the report, including the complete terms for long-term storage, what happens if a customer stops paying the annual fee, and the precise steps required to retrieve and use a sample. Cellino says release occurs at the owner’s request in coordination with a licensed physician, but the report does not spell out the clinical or regulatory requirements for any future use.
The distinction between established cryopreservation techniques and unproven future applications matters: the fact that cells can be stored does not show that they will later support a treatment. The service’s long-term value will depend on scientific advances and on evidence about the stored cells’ suitability for specific therapies.
As an affiliate, we earn on qualifying purchases.
Market Expansion and Long-Term Evidence
Cellino said it plans to expand Reservoir to additional markets beyond the launch locations. Adults can check local availability or join the company’s nationwide waitlist, while at-home collection remains limited to select areas, according to the report.
The next meaningful developments for consumers are likely to include broader availability and clearer information about storage terms, retrieval procedures and any clinical uses that emerge. Until research and medical practice establish specific applications, customers considering the service will need to weigh its current price and recurring storage fee against an uncertain future benefit.
personal immune cell storage service
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is Cellino’s Reservoir service?
Reservoir collects and stores immune cells from adults after a blood draw. Cellino says it isolates PBMCs, cryopreserves them and stores them for possible future medical use.
How much does immune cell banking cost?
The typical starting price is about $5,000, including collection, processing, preservation and the first year of storage. The reported annual storage fee afterward is $270, though prices vary by clinic.
Does banking immune cells improve longevity?
The source report does not establish that Reservoir improves longevity or health outcomes. Cellino presents it as a way to preserve cells for possible future use, and the value of that option remains uncertain.
Where is Reservoir available?
At launch, Cellino listed partner clinics in San Francisco, Los Angeles, New York and Boston, with at-home collection in select locations. The company said additional markets were planned and offered a nationwide waitlist.
Who can request the stored cells?
Cellino says members own their samples and can request their release in coordination with a licensed physician. The report does not detail the full process or requirements for using a sample in a future treatment.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
